Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 4/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | DDO | Q99489 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168742 | 0.90 | NPC1 (0.66) | MAOBNPC1RAB9APOLBLMNA | |
| SCHEMBL30395353 | 0.90 | NPC1 (0.66) | MAOBNPC1RAB9APOLBLMNA | |
| SCHEMBL34468802 | 0.88 | MEN1 (0.54) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL16627875 | 0.88 | ADORA3 (0.53) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL16627755 | 0.88 | MAOA (0.57) | MAOBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL21639712 | 0.86 | MAOA (0.58) | MAOBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16627766 | 0.84 | NPC1 (0.49) | MAOBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL34468752 | 0.84 | MAOB (0.60) | MAOBNPC1RAB9AMEN1POLB | |
| SCHEMBL21639567 | 0.83 | EGFR (0.54) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL16627822 | 0.83 | MAPT (0.58) | MAOBNPC1RAB9AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| WO-2015050379-A1 | NOVEL QUINOLINONE DERIVATIVE AND USE THEREOF | 광주과학기술원 | 2015-04-09 | — | — | WO | disclosed |
| EP-2411526-A2 | GANGLIOSIDE BIOSYNTHESIS MODULATORS | Zacharon Pharmaceuticals, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | MAOB 1062/4885NPC1 2864/4885RAB9A 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.